Search results
Results from the WOW.Com Content Network
Antiretroviral drugs are used to manage HIV/AIDS.Multiple antiretroviral drugs are often combined into a single pill in order to reduce pill burden.. Some of these combinations are complete single-tablet regimens; the others must be combined with additional pills to make a treatment regimen.
The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. [1] There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy ...
HIV antiretroviral HIV PI Delavirdine: HIV antiretroviral NNRTI Descovy (Emtricitabine/tenofovir alafenamide) Hepatitis B Emtricitabine: NRTI; Tenofovir alafenamide: NRTI; Didanosine: HIV Adenosine analogue RTI Docosanol: Herpes Simplex Entry inhibitor Dolutegravir: HIV Integrase inhibitor: Doravirine (Pifeltro) [7] HIV NNRTI Edoxudine: Herpes ...
HIV protease inhibitors (16 P) I. Integrase inhibitors (13 P) M. Maturation inhibitors (3 P) R. Reverse transcriptase inhibitors (2 C, 8 P) Pages in category ...
Zidovudine was the first antiretroviral drug approved by the FDA for the treatment of HIV. Didanosine, also called ddI, with the trade names Videx and Videx EC, was the second FDA-approved antiretroviral drug. It is an analog of adenosine.
Efavirenz (EFV), sold under the brand names Sustiva among others, is an antiretroviral medication used to treat and prevent HIV/AIDS. [1] It is generally recommended for use with other antiretrovirals. [1]
The maturation inhibitors are a class of antiviral drugs for the treatment of infection with HIV.They act by interfering with the maturation of the virus. Specifically, drugs in this class disrupt the final step in the processing of the HIV-1 gag protein, the cleavage of its immediate precursor by the enzyme HIV-1 protease.
Ritonavir is sold as Norvir by AbbVie, Inc. [4] [5] The US Food and Drug Administration (FDA) approved ritonavir on March 1, 1996, [41] [42] As a result of the introduction of "highly active antiretroviral thearap[ies]" the annual U.S. HIV-associated death rate fell from over 50,000 to about 18,000 over a period of two years. [40]